Clinical Trials Logo
  1. Home
  2. Advanced Lung Cancer
  3. NCT06106152

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer Clinical Trial

Official title:
A Single-center, Open Label, Exploratory Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of WTX212A Injection Combined With PD -1/PD-L1 Monoclonal Antibody in Patients With Advanced Lung Cancer

Clinical Trial Summary

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

Clinical Trial Description

The trial consist of Screening Period (30 days), Treatment Period (21*n days), Safety Follow-up Period (90 days) and Survival follow-up. About 20 subjects are planned to be enrolled in the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06106152
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact pingli wang, phD
Phone (0571)87783520
Email pingliwang@zju.edu.cn
Status Recruiting
Phase Early Phase 1
Start date December 5, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04575831 - Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) N/A
Completed NCT04069494 - Descriptors and Predictors of Burden and Information Needs
Terminated NCT03330834 - CAR-T Cell Immunotherapy for Advanced Lung Cancer Phase 1
Withdrawn NCT03004105 - MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT03501056 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer Phase 2
Not yet recruiting NCT05279521 - The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. N/A
Terminated NCT02768337 - Cambridge Brain Mets Trial 1 Phase 1/Phase 2
Completed NCT04672369 - A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC Phase 1
Recruiting NCT03751592 - Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05431569 - A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Phase 2
Not yet recruiting NCT06456138 - Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC Phase 1/Phase 2
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Completed NCT04672356 - A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer Phase 1
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Not yet recruiting NCT06107894 - TIL Therapy for Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06183762 - A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Recruiting NCT05664971 - JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer Phase 1/Phase 2
Recruiting NCT05815862 - Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer Phase 2
Recruiting NCT05805956 - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Phase 1/Phase 2
Recruiting NCT05000684 - Study of JS004 Combined With Toripalimab for Advanced Lung Cancer Phase 1/Phase 2